See more : Rolls-Royce Holdings plc (RR.L) Income Statement Analysis – Financial Results
Complete financial analysis of Spexis AG (SPEX.SW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Spexis AG, a leading company in the Biotechnology industry within the Healthcare sector.
- Cellnex Telecom, S.A. (CLNX.MC) Income Statement Analysis – Financial Results
- Oxford Square Capital Corp. (OXSQ) Income Statement Analysis – Financial Results
- Danske Invest Globale High Yield Obligationer (DKIGHYB.CO) Income Statement Analysis – Financial Results
- Planet Green Holdings Corp. (PLAG) Income Statement Analysis – Financial Results
- Properst Co., Ltd. (3236.T) Income Statement Analysis – Financial Results
Spexis AG (SPEX.SW)
About Spexis AG
Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase 1 development stage to treat Pseudomonas aeruginosa infection in people with CF; EBX-002 for non-tuberculous mycobacterial lung infections; Balixafortide for oncology and non-oncology indications; New CXCR4 for treating orphan and hematological malignancies, and non-oncology indications; and Outer Membrane Protein Targeting Antibiotic BamA and lipopolysaccharide transport protein A programs. Spexis AG is headquartered in Allschwil, Switzerland.
Source: https://incomestatements.info
Category: Stock Reports